aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Provided By GlobeNewswire
Last update: Feb 21, 2024
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis.
Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
Read more at globenewswire.com
